Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms (SPARE)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2009 by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Recruitment status was:  Active, not recruiting
Information provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Identifier:
First received: January 13, 2004
Last updated: April 8, 2009
Last verified: April 2009

January 13, 2004
April 8, 2009
September 2003
March 2009   (final data collection date for primary outcome measure)
Efficacy of a daily dose of purified soy isoflavone in preventing the rapid spinal bone loss occurring in early menopause [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00076050 on Archive Site
  • Effectiveness in preventing hot flashes and changes in vaginal cytology, lipids, and binding globulins [ Time Frame: yearly over 2 years ] [ Designated as safety issue: No ]
  • prevention of deterioration of general health-related quality of life and emotional health status generally occurring in early menopause [ Time Frame: over 2 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
Bone Sparing Effects of Soy Phytoestrogens in Menopause

The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause.

Study hypothesis: Tablets of high-dose, purified soy phytoestrogens spare the normally occurring spinal bone loss and improve biological and other emotional changes of menopause.

The risks of bone loss and osteoporosis increase significantly after menopause. Although hormone therapy (HT) can spare menopausal women from bone loss and other menopausal symptoms, Women's Health Initiative (WHI) findings indicate significant potential health risks associated with HT. This has prompted women to switch from HT to naturally occurring compounds similar to estrogen, such as those derived from soy, in the hope that estrogens from plant sources can provide benefits while sparing adverse effects caused by prescribed estrogens. However, the long-term efficacy and safety of plant estrogens are unknown. This study will evaluate the effectiveness of treatment using purified soy isoflavones, a dietary source of phytoestrogens, in preventing bone loss, menopausal symptoms, and other changes associated with estrogen deficiency in young menopausal women. The "Soy Phytoestrogens As Replacement Estrogen (SPARE)" study will provide a foundation of knowledge from which menopausal women and their doctors can begin to make more informed decisions regarding HT and other treatment options.

Enrollment into the study will occur over 3 years, with each participant taking part in the study for a total of 2 years. Participants will be randomly assigned to one of two groups; the first group will receive a 200 mg dose of soy isoflavones daily and the second group will receive placebo daily. There will be 10 study visits: screening, study entry, randomization at Month 1, six follow-up visits at Months 2, 4, 8, 12, 16, 20, and a final visit at the end of active participation at Month 24. At each study visit, participants will have blood drawn, provide urine samples, answer questionnaires, and have mammograms and bone density tests.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
  • Menopause
  • Osteoporosis
  • Osteopenia
  • Dietary Supplement: Soy isoflavones
    Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
  • Dietary Supplement: Placebo
    Placebo soy isoflavones
  • Experimental: 1
    Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
    Intervention: Dietary Supplement: Soy isoflavones
  • Placebo Comparator: 2
    Participants will receive placebo daily over 2 years.
    Intervention: Dietary Supplement: Placebo
Levis S, Strickman-Stein N, Ganjei-Azar P, Xu P, Doerge DR, Krischer J. Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med. 2011 Aug 8;171(15):1363-9. doi: 10.1001/archinternmed.2011.330.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
June 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Absence of menstrual period for 12 months but not more than 5 years, or absence of menstrual period for 6 to 12 months and follicle stimulating factor (FSH) greater than 40 IU/L

Exclusion Criteria

  • Treatment with estrogens, progesterone, raloxifene, or tamoxifen
  • Treatment with bisphosphonates, calcitonin, fluoride, or systemic corticosteroids
  • Use of soy/herbal supplements, including DHEA, within 3 months prior to study entry
  • Use of antibiotics in the month prior to study entry
  • Use of prescription medication to treat hot flashes
  • Chemical menopause, including post-chemotherapy
  • Hyperthyroidism
  • Hypothyroidism
  • Uncontrolled diabetes
  • Malabsorption syndromes or other chronic diseases
  • Body mass index (BMI) less than 20 or greater than 32
  • Bone mineral density (BMD) T-score below -2.0 in lumbar spine or femoral neck
45 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01AR048932, NIAMS-114, SPARE
Not Provided
Not Provided
Silvina Levis, MD, University of Miami
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not Provided
Principal Investigator: Silvina Levis, MD University of Miami
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP